Business Segments · Revenues:
Business Segments — Revenues:
Pfizer Business Segments — Revenues: increased by 5.4% to $14.16B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 5.4%, from $13.44B to $14.16B. This is a positive signal — higher values indicate stronger performance for this metric.
Analysis
StatementSegment
CategoryGrowth
SignalHigher is better
VolatilityStable
First reportedQ1 2017
Last reportedQ1 2026
Rolls up toTotal Revenue
How to read this metric
Higher revenues indicate strong product adoption, successful market penetration, or effective pricing strategies.
Detailed definition
The total gross income generated from the sale of pharmaceutical products, vaccines, and related services within the bio...
Peer comparison
The core top-line metric for all pharmaceutical companies, essential for benchmarking market share.
Metric ID:
pfe_segment_biopharma_revenuesHistorical Data
12 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q1 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $19.89B | $19.89B | $19.89B | $25.32B | $27.43B | $22.32B | $23.92B | $17.97B | $12.42B | $12.93B | $13.44B | $14.16B |
| QoQ Change | — | +0.0% | +0.0% | +27.3% | +8.3% | -18.6% | +7.2% | -24.9% | -30.9% | +4.1% | +4.0% | +5.4% |
| YoY Change | — | — | — | — | +37.9% | +12.2% | +20.3% | -29.0% | -54.7% | -42.1% | — | +5.4% |
Range$12.42B – $27.43B
CAGR-11.6%
Avg YoY Growth-7.2%
Median YoY Growth+5.4%
Current Streak3 quarters growth
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Pfizer's business segments — revenues:?
- Pfizer (PFE) reported business segments — revenues: of $14.16B in Q1 2026.
- How has Pfizer's business segments — revenues: changed year-over-year?
- Pfizer's business segments — revenues: increased by 5.4% year-over-year, from $13.44B to $14.16B.
- What does business segments — revenues: mean?
- Total sales generated by the biopharma business segment.